Posters Overview
The Blood-Brain Barrier (BBB) Parallel Artificial Membrane Permeability Assay (PAMPA) model is frequently employed to predict passive BBB penetration in the early stages of Central Nervous System (CNS) drug development, and MDR1-MDCK I cell from the National Institutes of Health (NIH) is mainly used to exclude P-glycoprotein (P-gp, MDR1) substrates for CNS drug development . The two models have traditionally been applied independently. In this study, we combined both models to create a novel funnel model for the precise evaluation of BBB penetration in the early stages of CNS drug development.
Complete the form to view and download this poster.
Stay Connected
Keep up with the latest news and insights.